Invivoscribe Marketing, Author at Invivoscribe

PRODUCTS
- Reagents
  ASRs
  Enzymes
  Hi-Di Formamide
- Product & Service Catalogs
CLINICAL LAB SERVICES
- Clinical Lab Services Overview
  The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.
  EXPLORE SERVICES ⟶
- Flow Cytometry
  Hematolymphoid Screening Panel
  AML MRD Assay
  CLL MRD Assay
- Companion Diagnostic (CDx) Tests
  CDx – USA
  CDx – Germany
  CDx – Japan
- NGS Cancer Panels
  MyAML
  MyMRD
- MRD NGS Tests
  Clonality
  FLT3 ITD
  NPM1
- Clonality NGS Tests
  SHM
  IGH
  IGK
  TRG
  TRB
BIOBANK REPOSITORY
DISEASES
- Lymphoid
  Mature B-cell
  Mature T-cell
  
  Lymphoma
  Lymphoma is a cancer that starts in cells that are part of the body’s immune system. Knowing which type of lymphoma you have is important because it affects your treatment options and your outlook (prognosis).
  
  LEARN MORE ⟶
- Myeloid
  Myelodysplastic Syndromes (MDS)
  Acute Myeloid Leukemia (AML)
  Myeloproliferative Neoplasms (MPNs)
  
  Myeloma
  Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system.
  
  LEARN MORE ⟶
- Hematological Testing Menu
  Browse our comprehensive menu of product & testing services.
  EXPLORE MENU ⟶
PARTNERSHIPS
- Partnerships Overview
  A proven strategy to accelerate drug approvals
  EXPLORE PARTNERSHIPS ⟶
  CE-IVD
  LeukoStrat products are used worldwide to determine the mutation status of the FLT3 and NPM1 biomarkers.
  LEARN MORE ⟶
- Product Development
  Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays
  EXPLORE ⟶
  CE-IVD
  IdentiClone assays are intended for PCR-based detection of clonal gene rearrangements and translocations.
  LEARN MORE ⟶
- Manufacturing
  cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents
  EXPLORE ⟶
- LabPMM®
  Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment
  EXPLORE ⟶
- Global Regulatory Expertise
  Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)
  EXPLORE ⟶
SCIENCE
- Science Overview
  We take pride in expanding the science that bridges personalized medicine with quality healthcare.
  EXPLORE OUR SCIENCE ⟶
- Personalized Medicine
  Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.
  EXPLORE PERSONALIZED MEDICINE ⟶
PUBLICATIONS
- Featured Publication
  Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia
  VIEW PUBLICATION ⟶
- Latest Publications
  Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia
  VIEW PUBLICATION ⟶
  Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing
  VIEW PUBLICATION ⟶
  Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma
  VIEW PUBLICATION ⟶
COMPANY
- Company
  About Us
  Our Mission, Vision & Values
  Leadership Team
  Board of Directors
  Legal Notices
  Newsroom
  Global Distributors
  Licensure and Certifications
  Careers & Culture
  Shop Corporate Gear
- Invivoscribe Locations
  
  Invivoscribe, Inc. (USA)
  San Diego, CA, US
  CONTACT US ⟶
  
  Invivoscribe, SARL (France)
  Marseille, France
  CONTACT US ⟶
  
  Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
  Shanghai, China
  CONTACT US ⟶
  Lymphoma
  Lymphoma is a cancer that starts in cells that are part of the body’s immune system. Knowing which type of lymphoma you have is important because it affects your treatment options and your outlook (prognosis).
  LEARN MORE ⟶
- Clinical Lab Locations
  
  LabPMM, LLC (USA)
  San Diego, CA, US
  CONTACT US ⟶
  
  LabPMM, GmbH (Germany)
  Munich, Germany
  CONTACT US ⟶
  
  LabPMM, GK (Japan)
  Kawasaki, Japan
  CONTACT US ⟶
  
  Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
  Shanghai, China
  CONTACT US ⟶
  Myeloma
  Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system.
  LEARN MORE ⟶
- Support
  
  Invivoscribe, Inc. (USA)
  CONTACT US ⟶
  
  Invivoscribe, SARL (France)
  CONTACT US ⟶
  
  Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
  CONTACT US ⟶
  
  LabPMM, LLC (USA)
  CONTACT US ⟶
  
  LabPMM, GmbH (Germany)
  CONTACT US ⟶
  
  LabPMM, GK (Japan)
  CONTACT US ⟶
  Search for:
Search
- Search Articles & Publications
  Search for:
- Search Products & Services
  SEARCH ⟶
- Search Product Documents & IFUs
  SEARCH ⟶

About Invivoscribe Marketing

This author has not yet filled in any details.
So far Invivoscribe Marketing has created 137 blog entries.

LabPMM Receives New York State Approval for the NPM1 MRD Assay – Informing Therapy and Accelerating Targeted Trials

Invivoscribe Marketing2025-06-17T21:44:30-07:00June 17th, 2025|2025 Press Releases, Press Releases|

From prognostication to precision in acute myeloid leukemia

Invivoscribe Marketing2025-05-08T16:47:49-07:00May 8th, 2025|2025 Publications, Featured Publications, Publications|

Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3 ITD mutated AML

Invivoscribe Marketing2025-05-09T09:20:30-07:00May 8th, 2025|2025 Publications, Featured Publications, Publications|

Invivoscribe Announces Registration of the LeukoStrat^® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland

Invivoscribe Marketing2025-03-28T10:05:45-07:00March 27th, 2025|2025 Press Releases, Press Releases|

Leveraging Highly Sensitive NGS FLT3-ITD and NPM1 MRD Assessments in AML

Invivoscribe Marketing2024-12-18T09:49:08-08:00December 7th, 2024|2024 Videos, Featured Videos, Videos|

Leveraging Highly Sensitive NGS Assays for Clonality, SHM and MRD Assessments

Invivoscribe Marketing2025-06-02T16:15:53-07:00September 23rd, 2024|2024 Videos, Featured Videos, Videos|

Innovations in MRD Detection: Leveraging NGS to Gain Insights into Multiple Myeloma and B-ALL

Invivoscribe Marketing2024-09-25T09:19:32-07:00September 17th, 2024|2024 Videos, Featured Videos, Videos|

Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 02

Invivoscribe Marketing2024-09-25T10:07:41-07:00June 25th, 2024|2024 Videos, Featured Videos, Videos|

Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 01

Invivoscribe Marketing2024-09-25T10:14:27-07:00June 25th, 2024|2024 Videos, Featured Videos, Videos|

Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers

Invivoscribe Marketing2024-06-21T12:55:12-07:00June 21st, 2024|2024 Publications, Featured Publications, Publications|

Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML

Invivoscribe Marketing2024-05-07T17:44:56-07:00May 8th, 2024|2024 Press Releases, Press Releases|

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Invivoscribe Marketing2024-05-02T11:47:00-07:00May 2nd, 2024|2024 Publications, Featured Publications, Publications|

Level Up Your MRD Testing: Leveraging Standardized & Sensitive AML Assessments

Invivoscribe Marketing2025-06-10T16:49:59-07:00March 20th, 2024|2024 Videos, Featured Videos, Videos|

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Invivoscribe Marketing2024-03-26T13:55:01-07:00March 20th, 2024|2024 Publications, Featured Publications, Publications|

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

Invivoscribe Marketing2024-03-26T13:50:51-07:00March 19th, 2024|2024 Publications, Featured Publications, Publications|

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

Invivoscribe Marketing2024-03-03T11:41:21-08:00March 1st, 2024|2024 Publications, Featured Publications, Publications|

The Evolving Role of NGS and Measurable Residual Disease in CLL/SLL and AML

Invivoscribe Marketing2025-06-10T16:52:28-07:00November 16th, 2023|2023 Videos, Featured Videos, Videos|

Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA

Invivoscribe Marketing2023-07-20T17:27:41-07:00July 21st, 2023|2023 Press Releases, Press Releases|

MRD Applications and Analysis

Invivoscribe Marketing2025-06-10T16:53:44-07:00June 20th, 2023|2023 Videos, Featured Videos, Videos|

Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research

Invivoscribe Marketing2023-06-05T12:37:16-07:00June 2nd, 2023|2023 Press Releases, Press Releases|

NGS Assessment of SHM in CLL/SLL: A Practical Comparison of Platforms and Primers

Invivoscribe Marketing2025-06-10T16:55:03-07:00May 31st, 2023|2023 Videos, Featured Videos, Videos|

Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan

Invivoscribe Marketing2023-05-25T17:09:22-07:00May 25th, 2023|2023 Press Releases, Press Releases|

Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay

Invivoscribe Marketing2023-05-11T03:12:47-07:00May 11th, 2023|2023 Press Releases, Press Releases|

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant

Invivoscribe Marketing2024-08-02T14:22:45-07:00March 7th, 2023|2023 Publications, Featured Publications, Publications|

Multiparameter Approach to CLL Diagnosis, Prognostic Biomarker Assessment, and MRD Monitoring

Invivoscribe Marketing2025-06-11T08:51:08-07:00February 28th, 2023|2023 Videos, Featured Videos, Videos|